It was a slimming week in the world of biotech.
Orexigen’s obesity drug, Contrave, was accepted for FDA review. Contrave joins weight-loss medicines from Arena and Vivus in the FDA hopper. Interestingly, all three are still seeking marketing partners, but there is a very real possibility that there will be an FDA-approved weight loss drug on the market soon.
Patients aren’t the only ones dropping weight. Amorfix dropped its vCJD program this week, and its CEO and 5 others are out as well. The company founder is back, along with the ProMIS rational drug design program.
Only The Cross-Border Biotech Blog is putting on weight. A new contributor, Wayne Schnarr, joined this week, bringing 30 years of industry experience and a fourth Ph.D. to the blog.